Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model

International Journal of Antimicrobial Agents

Volumn 25, Issue 5, 2005, Pages 409-413

  Firsov, Alexander A ^a   Alferova, Irene V ^a   Smirnova, Maria V ^a   Lubenko, Irene Yu ^a,b   Portnoy, Yury A ^a   Zinner, Stephen H ^c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b P K ANOKHIN INSTITUTE OF NORMAL PHYSIOLOGY   (Russian Federation)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ABT492; In vitro models; Pharmacodynamics

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 17644425653     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.02.004     Document Type: Article

References (11)

1. S.M. Gunderson, R.A. Hayes, and J.P. Quinn In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Antimicrob Agents Chemother 48 2004 203 208
2. Gustavson L, Hosmane B, Schweitzer S, et al. Pharmacokinetics and safety of multiple oral doses of ABT492. In: Programme and abstracts of the forty-third interscience conference on antimicrobial agents and chemotherapy, San-Diego, CA, USA. Washington, DC, USA: American Society for Microbiology; 2003. p. 4 [abstract A-16].
3. D.N. Fish, and A.T. Chow The clinical pharmacokinetics of levofloxacin Clin Pharmacokinet 32 1997 101 119
4. A.A. Firsov, and S.H. Zinner Use of modeling techniques to aid in antibiotic selection Curr Infect Dis Rep 3 2001 35 43
5. A.A. Firsov, S.N. Vostrov, and I.Y. Lubenko ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model J Antimicrob Chemother 54 2004 178 186
6. S.H. Zinner, S.N. Vostrov, and I.V. Alferova Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in-vitro dynamic model Int J Antimicrob Agents 24 2004 173 177
7. A.A. Firsov, A.A. Shevchenko, and S.N. Vostrov Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept Antimicrob Agents Chemother 42 1998 659 665
8. A.A. Firsov, D. Savarino, and M. Ruble Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC Antimicrob Agents Chemother 40 1996 734 738
9. E.A. Coyle, G.W. Kaatz, and M.J. Rybak Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 1654 1659
10. P.D. Lister, and C.C. Sanders Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae J Antimicrob Chemother 47 2001 811 818
11. E. Hershberger, and M.J. Rybak Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model Antimicrob Agents Chemother 44 2000 598 601